Online inquiry

IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12890MR)

This product GTTS-WQ12890MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12890MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10585MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ9277MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ9227MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-107
GTTS-WQ2829MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ2073MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AH-PD1
GTTS-WQ13949MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ483MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ10452MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2541546
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW